journal article·2022-10

Morphology-driven protein corona manipulation for preferential delivery of lipid nanodiscs

Tao Chen, Feng Pan, Gan Luo, Kuan Jiang, Huan Wang, Tianhao Ding, Wei Li, Changyou Zhan, Xiaoli Wei

Nano Today· Volume 46
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · Characterization and Applications of Magnetic Nanoparticles

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come10.1124/pr.115.012070 ↗
2. The role of liposomes in clinical nanomedicine development. What now? Now what?10.1016/j.jconrel.2019.12.023 ↗
3. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
4. 1 - PEGylated “stealth” nanoparticles and liposomes
5. Doxil®--the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
6. Liposomal formulations in clinical use: an updated review10.3390/pharmaceutics9020012 ↗
7. An mRNA vaccine against SARS-CoV-2 - preliminary report10.1056/NEJMoa2022483 ↗
8. The crown and the scepter: roles of the protein corona in nanomedicine10.1002/adma.201805740 ↗
9. A decade of the protein corona10.1021/acsnano.7b08008 ↗
10. The human in vivo biomolecule corona onto pegylated liposomes: a proof-of-concept clinical study
11. The protein corona of circulating PEGylated liposomes10.1016/j.bbamem.2015.11.012 ↗
12. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles10.1038/s41565-018-0344-3 ↗
13. Natural IgM dominates in vivo performance of liposomes10.1016/j.jconrel.2020.01.018 ↗
14. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents10.1517/17425247.2012.720969 ↗
15. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in thE General Population10.1021/acs.analchem.6b03437 ↗
16. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes10.1016/S0022-3565(24)35391-1 ↗
17. PEGylated liposomes: immunological responses10.1080/14686996.2019.1627174 ↗
18. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders10.1016/j.cld.2015.01.005 ↗
19. C-reactive protein for rapid diagnosis of infection in leukaemia10.1136/jcp.32.12.1253 ↗
20. Increase of serum complement levels in cancer patients with progressing tumors10.1002/1097-0142(197610)38:4<1608::AID-CNCR2820380427>3.0.CO;2-6 ↗
21. Plasma protein profiling: unique and stable features of individuals10.1002/pmic.200401234 ↗
22. Personalized protein corona on nanoparticles and its clinical implications10.1039/C6BM00921B ↗
23. Personalized liposome-protein corona in the blood of breast, gastric and pancreatic cancer patients10.1016/j.biocel.2015.09.002 ↗
24. Interplay between nanomedicine and protein corona10.1039/D1TB01063H ↗
25. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles10.1073/pnas.0608582104 ↗
26. Influence of surface chemistry and morphology of nanoparticles on protein corona formation10.1002/wnan.1788 ↗
27. Deciphering protein corona by scFv-based affinity chromatography10.1021/acs.nanolett.0c04806 ↗
28. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions10.1073/pnas.1106420108 ↗
29. Relaxation of backbone bond geometry improves protein energy landscape modeling10.1002/pro.2389 ↗
30. Algorithm discovery by protein folding game players10.1073/pnas.1115898108 ↗
31. Semi-automated optimization of the CHARMM36 lipid force field to include explicit treatment of long-range dispersion10.1021/acs.jctc.0c01326 ↗
32. CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling10.1021/ct200328p ↗
33. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers10.1016/j.softx.2015.06.001 ↗
34. Constant-pressure molecular-dynamics simulations of the crystal-smectic transition in systems of soft parallel spherocylinders10.1103/PhysRevA.46.6541 ↗
35. P-LINCS: a parallel linear constraint solver for molecular simulation10.1021/ct700200b ↗
36. Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines10.1016/j.jconrel.2020.12.047 ↗
37. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes10.4049/jimmunol.146.12.4234 ↗
38. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids10.1016/S0006-3495(03)74798-5 ↗
39. Unraveling GLUT-mediated transcytosis pathway of glycosylated nanodisks
40. Conformation of the free and antigen-bound IgM antibody molecules10.1038/2241307a0 ↗
41. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b10.1073/pnas.1901841116 ↗
42. Brain-targeted drug delivery by manipulating protein corona functions10.1038/s41467-019-11593-z ↗
43. Artificial apolipoprotein corona enables nanoparticle brain targeting10.1016/j.nano.2017.11.008 ↗
44. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage10.1016/j.jconrel.2013.07.026 ↗
45. Apolipoproteins adsorption and brain-targeting evaluation of baicalin nanocrystals modified by combination of Tween80 and TPGS10.1016/j.colsurfb.2017.10.009 ↗
46. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals10.1016/j.addr.2020.07.024 ↗